Search research articles
Contact Us
Filters
Showing results (1-10 of 166) with videos related to
Page
of 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
Tailoring a tailored treatment: the importance of fine-tuning on the patient
C Tondini, R Labianca
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2004
Adjuvant therapy for stage II colon cancer: an elephant in the living room?
A Zaniboni, R Labianca,
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2008
Introduction. Gemcitabine: ten years of clinical experience
G Cartei, R Labianca
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1991
5-fluorouracil cardiotoxicity: the risk of rechallenge
R Labianca, G Luporini
Pathologie-Biologie
|
January 1, 1993
Role of adjuvant chemotherapy and immunotherapy in gastric cancer
R Labianca, D Panvini
Tumori
|
March 20, 1999
[5-fluorouracil and colorectal tumors: use in clinical practice and the "MISURA" project]
R Labianca, P Poletti
Oncology
|
January 1, 1980
Cardiac toxicity from antitumor therapy
C Praga, G Beretta, R Labianca
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2002
Pre-operative endocrine therapy for postmenopausal women: when and why?
C Tondini, P Fenaroli, R Labianca
Journal of Surgical Oncology. Supplement
|
January 1, 1991
Chemotherapy for patients not benefitting from 5-fluorouracil therapy
G Luporini, R Labianca, G Pancera
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Predicting response of molecular targeted therapies: a still possible challenge?
R Labianca, M Garassino, V Torri
Page
of 17
Search research articles
Search
Showing results (1-10 of 166) with videos related to
Sort By:
Page
of 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
Tailoring a tailored treatment: the importance of fine-tuning on the patient
C Tondini, R Labianca
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2004
Adjuvant therapy for stage II colon cancer: an elephant in the living room?
A Zaniboni, R Labianca,
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2008
Introduction. Gemcitabine: ten years of clinical experience
G Cartei, R Labianca
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1991
5-fluorouracil cardiotoxicity: the risk of rechallenge
R Labianca, G Luporini
Pathologie-Biologie
|
January 1, 1993
Role of adjuvant chemotherapy and immunotherapy in gastric cancer
R Labianca, D Panvini
Tumori
|
March 20, 1999
[5-fluorouracil and colorectal tumors: use in clinical practice and the "MISURA" project]
R Labianca, P Poletti
Oncology
|
January 1, 1980
Cardiac toxicity from antitumor therapy
C Praga, G Beretta, R Labianca
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 2002
Pre-operative endocrine therapy for postmenopausal women: when and why?
C Tondini, P Fenaroli, R Labianca
Journal of Surgical Oncology. Supplement
|
January 1, 1991
Chemotherapy for patients not benefitting from 5-fluorouracil therapy
G Luporini, R Labianca, G Pancera
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Predicting response of molecular targeted therapies: a still possible challenge?
R Labianca, M Garassino, V Torri
Page
of 17